Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Making the Good Much Better Against Cancer

10.03.2014

Synthesis, Anti-tubulin and Antiproliferative Structure–Activity Relationship of Steroidomimetic Dihydroisoquinolinones


Tubulin, the building-block protein of cellular microtubules, is a well-validated cancer drug target: Disrupting tubulin polymerization affects cytoskeletal function and thus cell division. The vinca alkaloids, taxanes, and other taxane site binders have found wide therapeutic application and constitute one of the most successful classes of anticancer agent.

Nevertheless, current drugs that target tubulin still suffer from limited therapeutic window, acquired resistance, lack of oral bioavailability, and problematic formulation.

As reported in ChemMedChem, Barry Potter’s research group at the University of Bath (UK), along with colleagues at the NCI (USA), Ipsen (France), and Imperial College London, focused on a natural steroidal lead for introducing a new set of modifications that confer good oral activity and delivery and that impart resistance to metabolism.

"Two compounds showed in vitro anti-angiogenic activity, and X-ray analysis of one reveals that electrostatic repulsion between two adjacent carbonyl groups [...] dictates adoption of a 'steroid-like' conformation that might partially explain the excellent in vitro activities," says Potter. Indeed, the most active compounds are nearly equivalent to another compound currently in clinical trials as inhibitors of tubulin assembly, and some were shown to be anti-angiogenic. Moreover, the compounds are easily synthesized and amenable to aqueous formulation.

About the Author

Professor Barry Potter holds the established chair of Medicinal Chemistry at the University of Bath and is also Visiting Professor of Medicinal Chemistry at Oxford University. His research interests are in mechanistic enzymology, the chemistry of signal transduction, and anticancer drug design and discovery, and he has brought academically discovered drugs to multiple clinical trials. He is a Fellow of the Royal Society of Chemistry (RSC) and the Society of Biology, was elected to the UK National Academy of Medical Sciences, has won four interdisciplinary RSC medals, the GlaxoSmithKline International Achievement Award, and was named Investigator of the Year at the 2012 European Life Science Awards.

Author: Barry V. L. Potter, University of Bath (UK), http://www.bath.ac.uk/pharmacy/contacts/academics/barry_potter/

Title: Synthesis, Anti-tubulin and Antiproliferative SAR of Steroidomimetic Dihydroisoquinolinones

ChemMedChem, Permalink to the article: http://dx.doi.org/10.1002/cmdc.201400017

Barry V. L. Potter | Wiley VCH

Further reports about: Cancer RSC activity anti-angiogenic anticancer compounds drugs resistance therapeutic

More articles from Life Sciences:

nachricht Fungus deadly to AIDS patients found to grow on trees
22.08.2014 | Duke University

nachricht Canola genome sequence reveals evolutionary ‘love triangle’
22.08.2014 | University of Georgia

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Anzeige

Anzeige

Event News

MEDICA EDUCATION CONFERENCE: Bessere Behandlung dank Biomarker

21.08.2014 | Event News

Mathematics and Computer Science - Key Disciplines in Developing Countries as well?

20.08.2014 | Event News

5th Technical Conference "Subsoil Analysis, Ground Improvement and Wind Turbine Foundations"

13.08.2014 | Event News

 
Latest News

Yale's cool molecules

22.08.2014 | Physics and Astronomy

Fungus deadly to AIDS patients found to grow on trees

22.08.2014 | Life Sciences

Novel recycling methods: The fluorescent fingerprint of plastics

22.08.2014 | Ecology, The Environment and Conservation

VideoLinks
B2B-VideoLinks
More VideoLinks >>>